ARGX vs BIIB
Argenx SE and Biogen Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ARGX | BIIB |
|---|---|---|
| Revenue | $4.2B | $9.9B |
| Net income | $1.3B | $1.3B |
| Gross margin | 89.1% | 75.7% |
| Net margin | 31.1% | 13.1% |
| Return on equity | — | 11.0% |
| Diluted EPS | $19.57 | $8.79 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $679.0M | $2.1B |
| Equity | — | $14.8B |
| Net debt / equity | — | 0.41× |
| Current ratio | 5.23× | 2.68× |
| Revenue CAGR 5y | 151.5% | −6.0% |
| Profit CAGR 5y | — | −20.2% |
BIIB bills 2.4× the revenue of ARGX, and ARGX keeps more of each dollar of revenue as profit (31.1% against 13.1%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ARGX | BIIB |
|---|---|---|
| FY2025 | $4.2B | $9.9B |
| FY2024 | $2.2B | $9.7B |
| FY2023 | $1.2B | $9.8B |
| FY2022 | $400.7M | $10.2B |
| FY2021 | $497.3M | $11.0B |
| FY2020 | $41.2M | $13.4B |
| FY2019 | $78.5M | $14.4B |
| FY2018 | $21.5M | $13.5B |
| FY2017 | $36.4M | $12.3B |
| FY2016 | $14.7M | $11.4B |
Net income by year
Bottom line
| Fiscal year | ARGX | BIIB |
|---|---|---|
| FY2025 | $1.3B | $1.3B |
| FY2024 | $833.0M | $1.6B |
| FY2023 | $-295.1M | $1.2B |
| FY2022 | $-709.6M | $3.0B |
| FY2021 | $-408.3M | $1.6B |
| FY2020 | $-608.5M | $4.0B |
| FY2019 | $-181.2M | $5.9B |
| FY2018 | $-66.6M | $4.4B |
| FY2017 | $-28.1M | $2.5B |
| FY2016 | $-21.4M | $3.7B |
Advertisement
AdSense · Rectangle 336×280
More in this industry